<DOC>
	<DOCNO>NCT00072319</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , cyclophosphamide , paclitaxel , use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . Giving chemotherapy drug surgery may kill remain tumor cell . PURPOSE : Pilot trial study effectiveness neoadjuvant adjuvant epirubicin , cyclophosphamide , paclitaxel treat woman stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Adjuvant Epirubicin , Cyclophosphamide , Paclitaxel Treating Women With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility safety neoadjuvant adjuvant epirubicin , cyclophosphamide , paclitaxel , term absence grade 3 high toxicity ( aside alopecia ) , woman high-risk stage I-III breast cancer . OUTLINE : This pilot study . - Neoadjuvant adjuvant EC therapy : Patients receive epirubicin IV 3-5 minute cyclophosphamide IV ( EC ) day 1 filgrastim ( G-CSF ) subcutaneously day 2-9 10 . Treatment repeat every 10-11 day 4 course absence disease progression unacceptable toxicity . - Neoadjuvant adjuvant paclitaxel therapy : After completion EC therapy , patient receive paclitaxel IV 3 hour day 1 . Patients also receive G-CSF EC therapy . Treatment repeat every 10-11 day 4 course absence disease progression unacceptable toxicity . Patients prior surgery undergo definitive surgery completion chemotherapy . Patients also may receive adjuvant radiotherapy and/or hormonal therapy discretion treat physician . Patients follow every 4 month 3 year every 6 month 2 year . PROJECTED ACCRUAL : A total 11-38 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Stage I , II , III Inflammatory breast cancer allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase great ULN OR SGOT/SGPT great ULN AND alkaline phosphatase great 4 time ULN Renal Not specify Cardiovascular LVEF least low limit normal MUGA echocardiogram No unstable angina No congestive heart failure No arrhythmia require medical therapy No myocardial infarction within past year Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergy/hypersensitivity study drug drug formulate Cremophor EL No psychiatric illness would preclude understanding nature study study compliance No active unresolved infection No peripheral neuropathy great grade 1 No nonmammary malignancy within past 5 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix No concurrent medical condition would preclude study participation judgment investigator PRIOR CONCURRENT THERAPY : Biologic therapy More 12 month since prior immunotherapy prior breast cancer No prior concurrent biologic therapy immunotherapy breast cancer Chemotherapy More 12 month since prior chemotherapy prior breast cancer No prior anthracycline ( i.e. , doxorubicin epirubicin ) taxane therapy No prior concurrent chemotherapy breast cancer Endocrine therapy No concurrent hormonal therapy chemoprevention Prior hormonal therapy chemoprevention allow No concurrent sex hormonal therapy ( e.g. , birth control pills ovarian hormonal replacement therapy ) Radiotherapy No prior radiotherapy No concurrent radiotherapy breast cancer Surgery Not specify Other No concurrent digitalis , betablockers , calcium channel blocker congestive heart failure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>